Key result
Intravenous mioflazine pretreatment allowed all dogs to survive one hour of normothermic global ischaemia, whereas no control dogs recovered sufficiently to support circulation.
Why the study?
Does intravenous mioflazine pretreatment protect against ischemic damage in dogs on cardiopulmonary bypass?
Does intravenous mioflazine pretreatment protect against ischemic damage in dogs on cardiopulmonary bypass?
Intravenous mioflazine pretreatment protects against ischemic damage and preserves left ventricular function in a canine model of global ischemia.
Mioflazine pretreatment protects canine myocardium during ischemia; leaves open translation to human cardiopulmonary bypass.
The protective effect of intravenous mioflazine pretreatment was examined in intact dogs on cardiopulmonary bypass. The mechanical function of the left ventricle was measured by isovolumic pressure-volume relationships. Mioflazine alone had no inotropic effect. After one hour of normothermic (37 degrees C) global ischaemia of the whole heart, no control hearts, pretreated with solvent, recovered sufficiently to support the animal's circulation; this was not the case with animals pretreated with mioflazine, they all survived. After the 30-min reperfusion period, the solvent (control) pretreated hearts had a significantly lower (P = 0.05) systolic and higher (P = 0.001) diastolic pressure-volume curve than those given mioflazine.
No takes yet. Share an insight, caveat, or question.
Wood et al. (1985) studied Ischaemic damage. Intravenous mioflazine vs. Solvent (control) was evaluated on Recovery to support circulation/survival after 1 hour of global ischaemia. Intravenous mioflazine pretreatment allowed all dogs to survive one hour of normothermic global ischaemia, whereas no control dogs recovered sufficiently to support circulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: